Investor · 1 deal
Melbourne, VIC
Every published round University of Melbourne Endowment took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies University of Melbourne Endowment has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Hatchtech | Developing a new treatment for head lice | 8 Dec 2008, Grant | 1 | 0 |
Fund closes reported for University of Melbourne Endowment, as distinct from the investments it has made.
Companies University of Melbourne Endowment has backed that another company then bought. An exit for the holding, not a deal University of Melbourne Endowment did.
Stories naming University of Melbourne Endowment. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Hatchtech announced FDA sign-off on its DeOvo Phase 3 trials and two extra patents; its profile names GBS Venture Partners among the company's investors.
Melbourne drug developer Hatchtech raised A$12.6 million, with OneVentures Innovation Fund leading, to advance its head lice treatment toward Phase III trials; board changes brought in Richard Treagus and Hugh Alsop.
Australian pharmaceutical developer Hatchtech appoints Tim Waugh, a former Roche divisional vice president, as chief executive officer to lead development and commercialisation of its head lice treatment DeOvo and establish a United States presence.